180 related articles for article (PubMed ID: 2534084)
1. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients.
Collier A; Watson HH; Patrick AW; Ludlam CA; Clarke BF
Diabete Metab; 1989; 15(6):420-5. PubMed ID: 2534084
[TBL] [Abstract][Full Text] [Related]
2. Effect of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG and lipid peroxides in non-insulin dependent diabetes mellitus.
Florkowski CM; Richardson MR; Le Guen C; Jennings PE; O'Donnell MJ; Jones AF; Lunec J; Barnett AH
Diabetes Res; 1988 Oct; 9(2):87-90. PubMed ID: 3149923
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
[TBL] [Abstract][Full Text] [Related]
4. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
5. A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.
McAlpine LG; McAlpine CH; Waclawski ER; Storer AM; Kay JW; Frier BM
Eur J Clin Pharmacol; 1988; 34(2):129-32. PubMed ID: 3289948
[TBL] [Abstract][Full Text] [Related]
6. The effects of diet and insulin therapy on coagulation factor VII, blood viscosity, and platelet release proteins in diabetic patients with secondary sulphonylurea failure.
Jennings AM; Ford I; Murdoch S; Greaves M; Preston FE; Ward JD
Diabet Med; 1991 May; 8(4):346-53. PubMed ID: 1830258
[TBL] [Abstract][Full Text] [Related]
7. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
[TBL] [Abstract][Full Text] [Related]
8. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
Noury J; Nandeuil A
Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
[TBL] [Abstract][Full Text] [Related]
9. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of platelet reactivity in diabetes mellitus.
Kutti J; Wadenvik H; Henestam B; Stenström G
Acta Med Scand; 1986; 219(2):195-9. PubMed ID: 2938425
[TBL] [Abstract][Full Text] [Related]
11. Hemobiological activity of gliclazide in diabetes mellitus.
Ziegler O; Drouin P
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S83-9. PubMed ID: 1794271
[TBL] [Abstract][Full Text] [Related]
12. Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.
Zurro Hernandez J; Lavielle R
Curr Med Res Opin; 1986; 10(5):351-8. PubMed ID: 3816294
[TBL] [Abstract][Full Text] [Related]
13. Free radical scavenging activity of sulfonylureas: a clinical assessment of the effect of gliclazide.
Jennings PE; Belch JJ
Metabolism; 2000 Feb; 49(2 Suppl 1):23-6. PubMed ID: 10693916
[TBL] [Abstract][Full Text] [Related]
14. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Roden M; Mariz S; Brazzale AR; Pacini G
J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
Derosa G; Gaddi AV; Piccinni MN; Salvadeo S; Ciccarelli L; Fogari E; Ghelfi M; Ferrari I; Cicero AF
Diabetes Obes Metab; 2006 Mar; 8(2):197-205. PubMed ID: 16448524
[TBL] [Abstract][Full Text] [Related]
17. Sulfonylureas and platelet function.
Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
Guillausseau PJ
Diabet Med; 1997 Sep; 14(9):798-802. PubMed ID: 9300232
[TBL] [Abstract][Full Text] [Related]
19. Hemobiological properties of gliclazide.
Ziegler O; Drouin P
J Diabetes Complications; 1994; 8(4):235-9. PubMed ID: 7833500
[TBL] [Abstract][Full Text] [Related]
20. Anti-platelet effects of long-term treatment with gliclazide in diabetic patients.
Ponari O; Civardi E; Megha S; Pini M; Portioli D; Dettori AG
Thromb Res; 1979; 16(1-2):191-203. PubMed ID: 116387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
